Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant

Article Public, Environmental & Occupational Health

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022

Anne M. Hause et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Article Medicine, General & Internal

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19

Kathryn E. Stephenson et al.

Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Virology

Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays

Jingyou Yu et al.

Summary: The study outlines a method to generate a highly infectious SARS-CoV-2 pseudovirus for evaluating humoral immunity, antibody therapeutics, and vaccines. The SDCT13-based pseudovirus neutralization assay exhibits key characteristics including linearity, limit of detection, and assay precision. This assay is adaptable for emerging SARS-CoV-2 variants and crucial for the development of vaccines and immune-based therapeutics.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

Ann R. Falsey et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants

Amarendra Pegu et al.

Summary: The study assessed the impact of SARS-CoV-2 variants on antibody responses induced by the mRNA vaccine over 7 months, showing that most individuals maintained binding and functional antibodies against variants, with B.1.351 having the lowest antibody recognition.

SCIENCE (2021)

Add to Collection

Article Public, Environmental & Occupational Health